Pfizer's Torisel fails in Phase III second-line kidney cancer trial
This article was originally published in Scrip
Pfizer insists that its mTOR inhibitor Torisel (temsirolimus) "continues to be an important part of Pfizer's portfolio of therapies for advanced kidney cancer" even though a Phase III study investigating the drug as second-line treatment in advanced renal cell carcinoma (RCC) has failed to meet its primary endpoint.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.